NEW YORK--(BUSINESS WIRE)--
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of United Therapeutics Corporation (NASDAQ: UTHR) resulting from allegations that United Therapeutics may have issued materially misleading business information to the investing public.
On July 27, 2017, United Therapeutics disclosed that it recorded a $210 million accrual relating to a potential settlement in connection with a U.S. Department of Justice investigation of United Therapeutics concerning possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act. On this news, shares of United Therapeutics fell sharply during intraday trading on July 27, 2017, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by United Therapeutics investors. If you purchased shares of United Therapeutics on or before July 27, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1170.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170727006530/en/
